NO300683B1 - Substituerte cyklopropylamino-1,3,5-triaziner - Google Patents
Substituerte cyklopropylamino-1,3,5-triaziner Download PDFInfo
- Publication number
- NO300683B1 NO300683B1 NO922922A NO922922A NO300683B1 NO 300683 B1 NO300683 B1 NO 300683B1 NO 922922 A NO922922 A NO 922922A NO 922922 A NO922922 A NO 922922A NO 300683 B1 NO300683 B1 NO 300683B1
- Authority
- NO
- Norway
- Prior art keywords
- cyclopropylamino
- triazine
- thiomorpholino
- compound
- pharmaceutically acceptable
- Prior art date
Links
- PFVKYIGBPAAFOC-UHFFFAOYSA-N n-cyclopropyl-1,3,5-triazin-2-amine Chemical class C1CC1NC1=NC=NC=N1 PFVKYIGBPAAFOC-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- -1 bis(2-hydroxyethyl)amino, 3-hydroxy-1-azetidinyl Chemical group 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims description 14
- 231100000252 nontoxic Toxicity 0.000 claims description 14
- 230000003000 nontoxic effect Effects 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- BEALUMZSRZJBDR-UHFFFAOYSA-N n-cyclopropyl-4-morpholin-4-yl-6-propyl-1,3,5-triazin-2-amine Chemical group N=1C(N2CCOCC2)=NC(CCC)=NC=1NC1CC1 BEALUMZSRZJBDR-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- FSNZHRXDXKICIO-UHFFFAOYSA-N n,4-dicyclopropyl-6-thiomorpholin-4-yl-1,3,5-triazin-2-amine Chemical group C1CC1NC1=NC(C2CC2)=NC(N2CCSCC2)=N1 FSNZHRXDXKICIO-UHFFFAOYSA-N 0.000 claims description 3
- KUXUCOWAIICKHG-UHFFFAOYSA-N 4-cyclobutyl-n-cyclopropyl-6-morpholin-4-yl-1,3,5-triazin-2-amine Chemical group C1CC1NC1=NC(C2CCC2)=NC(N2CCOCC2)=N1 KUXUCOWAIICKHG-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- RUOPUQSDCJSPQX-UHFFFAOYSA-N n,4-dicyclopropyl-6-morpholin-4-yl-1,3,5-triazin-2-amine Chemical group C1CC1NC1=NC(C2CC2)=NC(N2CCOCC2)=N1 RUOPUQSDCJSPQX-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 28
- 238000002360 preparation method Methods 0.000 abstract description 15
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 5
- 125000005505 thiomorpholino group Chemical group 0.000 abstract description 5
- 125000000217 alkyl group Chemical group 0.000 abstract description 4
- 208000006673 asthma Diseases 0.000 abstract description 4
- 230000001149 cognitive effect Effects 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000007170 pathology Effects 0.000 abstract description 4
- 208000019901 Anxiety disease Diseases 0.000 abstract description 3
- 230000036506 anxiety Effects 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 3
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 208000019022 Mood disease Diseases 0.000 abstract description 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 241001465754 Metazoa Species 0.000 description 33
- 239000000243 solution Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 24
- 229960001340 histamine Drugs 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 230000008018 melting Effects 0.000 description 17
- 238000002844 melting Methods 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 210000003714 granulocyte Anatomy 0.000 description 15
- 229960001317 isoprenaline Drugs 0.000 description 15
- 210000003622 mature neutrocyte Anatomy 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 13
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 13
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 13
- 229960002646 scopolamine Drugs 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 229960000278 theophylline Drugs 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 230000008602 contraction Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 230000000862 serotonergic effect Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 229940092253 ovalbumin Drugs 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 150000000182 1,3,5-triazines Chemical class 0.000 description 5
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 230000002052 anaphylactic effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- KCOZKSLUHKPGIG-UHFFFAOYSA-N 1-cyano-2-cyclopropylguanidine Chemical compound N#CNC(=N)NC1CC1 KCOZKSLUHKPGIG-UHFFFAOYSA-N 0.000 description 4
- 208000000104 Arthus reaction Diseases 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000003109 amnesic effect Effects 0.000 description 4
- 230000003501 anti-edematous effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 4
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- HKVQTTYKBFURJZ-UHFFFAOYSA-N 4-(4-chloro-6-cyclopropyl-1,3,5-triazin-2-yl)morpholine Chemical compound N=1C(Cl)=NC(C2CC2)=NC=1N1CCOCC1 HKVQTTYKBFURJZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000048 adrenergic agonist Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000006986 amnesia Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000000572 bronchospasmolytic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 238000011597 hartley guinea pig Methods 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000001670 myorelaxant effect Effects 0.000 description 3
- QPIFDHOKMJTDQF-UHFFFAOYSA-N n,4-dicyclopropyl-6-(1,3-thiazolidin-3-yl)-1,3,5-triazin-2-amine Chemical compound C1CC1NC1=NC(C2CC2)=NC(N2CSCC2)=N1 QPIFDHOKMJTDQF-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 3
- 229960001697 physostigmine Drugs 0.000 description 3
- XMOPVCIMGZUNNI-UHFFFAOYSA-N tert-butyl 1,3-thiazolidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCSC1 XMOPVCIMGZUNNI-UHFFFAOYSA-N 0.000 description 3
- ADVXAMGGIRUOKU-UHFFFAOYSA-N 2,4-dichloro-6-ethyl-1,3,5-triazine Chemical compound CCC1=NC(Cl)=NC(Cl)=N1 ADVXAMGGIRUOKU-UHFFFAOYSA-N 0.000 description 2
- HTSVYUUXJSMGQC-UHFFFAOYSA-N 2-chloro-1,3,5-triazine Chemical compound ClC1=NC=NC=N1 HTSVYUUXJSMGQC-UHFFFAOYSA-N 0.000 description 2
- HSAAMRFQNBUTKK-UHFFFAOYSA-N 4-chloro-n-cyclopropyl-1,3,5-triazin-2-amine Chemical compound ClC1=NC=NC(NC2CC2)=N1 HSAAMRFQNBUTKK-UHFFFAOYSA-N 0.000 description 2
- UTQMJAKKVFHHDI-UHFFFAOYSA-N 4-chloro-n-cyclopropyl-6-methyl-1,3,5-triazin-2-amine Chemical compound CC1=NC(Cl)=NC(NC2CC2)=N1 UTQMJAKKVFHHDI-UHFFFAOYSA-N 0.000 description 2
- IOQLIWZCDKFYKA-UHFFFAOYSA-N 4-chloro-n-cyclopropyl-6-propyl-1,3,5-triazin-2-amine Chemical compound CCCC1=NC(Cl)=NC(NC2CC2)=N1 IOQLIWZCDKFYKA-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229960004205 carbidopa Drugs 0.000 description 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009501 mnemonic process Effects 0.000 description 2
- LSIRSEUDGBFSAZ-UHFFFAOYSA-N n,4-dicyclopropyl-6-morpholin-4-yl-1,3,5-triazin-2-amine;hydrochloride Chemical compound Cl.C1CC1NC1=NC(C2CC2)=NC(N2CCOCC2)=N1 LSIRSEUDGBFSAZ-UHFFFAOYSA-N 0.000 description 2
- IRETVFGTMNOZTR-UHFFFAOYSA-N n-cyclopropyl-4-(1-methylcyclopropyl)-6-morpholin-4-yl-1,3,5-triazin-2-amine Chemical compound N=1C(NC2CC2)=NC(N2CCOCC2)=NC=1C1(C)CC1 IRETVFGTMNOZTR-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000008557 oxygen metabolism Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000952 serotonin receptor agonist Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000003506 spasmogen Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- AQKUXLUTDNNRLD-UHFFFAOYSA-N tert-butyl 1,1-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCS(=O)(=O)C1 AQKUXLUTDNNRLD-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SKBXVAOMEVOTGJ-UHFFFAOYSA-N xi-Pinol Chemical compound CC1=CCC2C(C)(C)OC1C2 SKBXVAOMEVOTGJ-UHFFFAOYSA-N 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- ATACNVMRCBZPPS-UHFFFAOYSA-N 1,3-thiazolidine 1,1-dioxide;hydrochloride Chemical compound Cl.O=S1(=O)CCNC1 ATACNVMRCBZPPS-UHFFFAOYSA-N 0.000 description 1
- CPEONABTMRSIKA-UHFFFAOYSA-N 1,4$l^{2}-oxazinane Chemical compound C1COCC[N]1 CPEONABTMRSIKA-UHFFFAOYSA-N 0.000 description 1
- IZCGKNRWYPPLKT-UHFFFAOYSA-N 1-cyano-1-cyclopropylguanidine Chemical compound NC(=N)N(C#N)C1CC1 IZCGKNRWYPPLKT-UHFFFAOYSA-N 0.000 description 1
- XKQXYIWXEKIVGQ-UHFFFAOYSA-N 1-hydroxy-2h-1,3,5-triazine Chemical class ON1CN=CN=C1 XKQXYIWXEKIVGQ-UHFFFAOYSA-N 0.000 description 1
- RHYYBHZFUCSINS-UHFFFAOYSA-N 2,4-dichloro-6-cyclopropyl-1,3,5-triazine Chemical compound ClC1=NC(Cl)=NC(C2CC2)=N1 RHYYBHZFUCSINS-UHFFFAOYSA-N 0.000 description 1
- BFUGAHPTVMZLAC-UHFFFAOYSA-N 2,4-dichloro-6-methyl-1,3,5-triazine Chemical compound CC1=NC(Cl)=NC(Cl)=N1 BFUGAHPTVMZLAC-UHFFFAOYSA-N 0.000 description 1
- CYCJLDRPFYTAMJ-UHFFFAOYSA-N 2-(trifluoromethyl)-1,3,5-triazine Chemical class FC(F)(F)C1=NC=NC=N1 CYCJLDRPFYTAMJ-UHFFFAOYSA-N 0.000 description 1
- SHCUVJVACNVUPK-UHFFFAOYSA-M 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium;iodide Chemical compound [I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC SHCUVJVACNVUPK-UHFFFAOYSA-M 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- UPJMYILFLDLYNH-UHFFFAOYSA-N 2-cyclopropyl-1-(diaminomethylidene)guanidine Chemical class NC(=N)NC(=N)NC1CC1 UPJMYILFLDLYNH-UHFFFAOYSA-N 0.000 description 1
- AYTUUEWDUBHMBC-UHFFFAOYSA-N 2-cyclopropylguanidine Chemical compound NC(=N)NC1CC1 AYTUUEWDUBHMBC-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LOFDNEZOFWQNJW-UHFFFAOYSA-N 4-chloro-6-cyclobutyl-n-cyclopropyl-1,3,5-triazin-2-amine Chemical compound N=1C(C2CCC2)=NC(Cl)=NC=1NC1CC1 LOFDNEZOFWQNJW-UHFFFAOYSA-N 0.000 description 1
- SUDLXPQVHDMSPD-UHFFFAOYSA-N 4-chloro-n,6-dicyclopropyl-1,3,5-triazin-2-amine Chemical compound N=1C(C2CC2)=NC(Cl)=NC=1NC1CC1 SUDLXPQVHDMSPD-UHFFFAOYSA-N 0.000 description 1
- FIAAFBMZIJNVHT-UHFFFAOYSA-N 4-chloro-n-cyclopropyl-6-ethyl-1,3,5-triazin-2-amine Chemical compound CCC1=NC(Cl)=NC(NC2CC2)=N1 FIAAFBMZIJNVHT-UHFFFAOYSA-N 0.000 description 1
- PFHHTWSPZYDFEK-UHFFFAOYSA-N 4-chloro-n-cyclopropyl-6-propan-2-yl-1,3,5-triazin-2-amine Chemical compound CC(C)C1=NC(Cl)=NC(NC2CC2)=N1 PFHHTWSPZYDFEK-UHFFFAOYSA-N 0.000 description 1
- GOIPIEMTOZZMNH-UHFFFAOYSA-N 4-morpholin-4-yl-6-propyl-1,3,5-triazin-2-amine Chemical class CCCC1=NC(N)=NC(N2CCOCC2)=N1 GOIPIEMTOZZMNH-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N 8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1O2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- RFBXEQYQSIJAJL-UHFFFAOYSA-N azetidin-3-one;hydron;chloride Chemical compound Cl.O=C1CNC1 RFBXEQYQSIJAJL-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- SIIJRCRHAIMFNT-UHFFFAOYSA-N cyclopropanamine;hydrochloride Chemical compound Cl.NC1CC1 SIIJRCRHAIMFNT-UHFFFAOYSA-N 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- IZPYNZLFBUQGCZ-UHFFFAOYSA-N ethyl 1-methylcyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(C)CC1 IZPYNZLFBUQGCZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- BPINQUNXHMOXTB-UHFFFAOYSA-N n'-(n'-cyclopropylcarbamimidoyl)morpholine-4-carboximidamide;hydrochloride Chemical compound Cl.C1COCCN1C(=N)NC(=N)NC1CC1 BPINQUNXHMOXTB-UHFFFAOYSA-N 0.000 description 1
- BRTGPBRROCDNOA-UHFFFAOYSA-N n-cyclopropyl-4-(2-methylcyclopropyl)-6-morpholin-4-yl-1,3,5-triazin-2-amine;hydrochloride Chemical compound Cl.CC1CC1C1=NC(NC2CC2)=NC(N2CCOCC2)=N1 BRTGPBRROCDNOA-UHFFFAOYSA-N 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002901 organomagnesium compounds Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Epoxy Resins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919116039A GB9116039D0 (en) | 1991-07-25 | 1991-07-25 | Substituted cyclopropylamino-1,3,5-triazines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922922D0 NO922922D0 (no) | 1992-07-23 |
| NO922922L NO922922L (no) | 1993-01-26 |
| NO300683B1 true NO300683B1 (no) | 1997-07-07 |
Family
ID=10698941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922922A NO300683B1 (no) | 1991-07-25 | 1992-07-23 | Substituerte cyklopropylamino-1,3,5-triaziner |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5258513A (ko) |
| EP (1) | EP0527117B1 (ko) |
| JP (1) | JP3138540B2 (ko) |
| KR (1) | KR100221400B1 (ko) |
| AT (1) | ATE159719T1 (ko) |
| AU (1) | AU648424B2 (ko) |
| CA (1) | CA2072680A1 (ko) |
| DE (1) | DE69222903T2 (ko) |
| DK (1) | DK0527117T3 (ko) |
| ES (1) | ES2109332T3 (ko) |
| FI (1) | FI923314A (ko) |
| GB (1) | GB9116039D0 (ko) |
| GR (1) | GR3026017T3 (ko) |
| HU (1) | HU218207B (ko) |
| IE (1) | IE922422A1 (ko) |
| NO (1) | NO300683B1 (ko) |
| NZ (1) | NZ243681A (ko) |
| PL (2) | PL169247B1 (ko) |
| RU (1) | RU2095353C1 (ko) |
| UA (1) | UA27749C2 (ko) |
| ZA (1) | ZA924920B (ko) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
| US5488056A (en) * | 1994-10-31 | 1996-01-30 | Eli Lilly And Company | Method for treating anxiety |
| US6400819B1 (en) * | 1996-03-28 | 2002-06-04 | Hitachi, Ltd. | Method and apparatus for executing communication in real-time and data structure for real-time data communication |
| WO1998011076A1 (de) * | 1996-09-13 | 1998-03-19 | Lonza Ag | Verfahren zur herstellung von 6-methyl-2-methylamino-4-methoxy-1,3,5-triazin |
| US6292261B1 (en) | 1998-05-22 | 2001-09-18 | Cyberoptics Corporation | Rotary sensor system with at least two detectors |
| US6538750B1 (en) | 1998-05-22 | 2003-03-25 | Cyberoptics Corporation | Rotary sensor system with a single detector |
| FI105684B (fi) * | 1998-08-21 | 2000-09-29 | Neste Chemicals Oy | Enantioselektiiviset kiraaliset sulfidikatalyytit, menetelmä niiden valmistamiseksi ja niiden käyttö stereoselektiivisiin epoksidointi-, syklopropanointi- ja atsiridinointireaktioihin |
| US6384032B1 (en) * | 1999-06-17 | 2002-05-07 | Shionogi Bioresearch Corp. | Inhibitors of IL-12 production |
| AU781849C (en) * | 1999-06-17 | 2006-03-02 | Synta Pharmaceuticals Corp. | Inhibitors of IL-12 production |
| DE60043318D1 (de) | 1999-08-21 | 2010-01-14 | Nycomed Gmbh | Synergistische kombination von pumafentrine und salmeterol |
| CN1098876C (zh) * | 1999-09-21 | 2003-01-15 | 上海赛璐化工股份有限公司 | 一种长碳链共聚酰胺及其制备方法 |
| US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
| US6680315B2 (en) * | 2000-06-15 | 2004-01-20 | Synta Pharmaceuticals Corp. | Triazine compounds |
| US7323462B2 (en) * | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| KR20050115331A (ko) | 2003-04-01 | 2005-12-07 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 불임증 포스포디에스터라제의 억제제 |
| EP1689403A4 (en) * | 2003-11-10 | 2007-09-05 | Synta Pharmaceuticals Corp | HETEROARYL-hydrazone compounds |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US9580471B2 (en) | 2011-03-01 | 2017-02-28 | Synergy Pharmaceuticals, Inc. | Process of preparing guanylate cyclase C agonists |
| US9321742B2 (en) * | 2011-08-08 | 2016-04-26 | Immunomet Therapeutics Inc. | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| US9545446B2 (en) | 2013-02-25 | 2017-01-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| JP6694385B2 (ja) | 2013-08-09 | 2020-05-13 | アーデリクス，インコーポレーテッド | リン酸塩輸送阻害のための化合物及び方法 |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160831A (en) * | 1976-08-19 | 1979-07-10 | Ciba-Geigy Corporation | Novel insecticides |
| EP0003749B1 (de) * | 1978-02-03 | 1982-09-15 | Ciba-Geigy Ag | 2-Methylthio-4-cyclopropylamino-6-(Alpha,Beta-dimethylpropylamino)-s-triazin und die Verwendung von Triazinderivaten als Meerwasseralgizide |
| GB8819494D0 (en) * | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
| GB8819493D0 (en) * | 1988-08-16 | 1988-09-21 | Ucb Sa | 2-amino-4-morpholino-6-propyl-1 3 5-triazines |
-
1991
- 1991-07-25 GB GB919116039A patent/GB9116039D0/en active Pending
-
1992
- 1992-06-29 CA CA002072680A patent/CA2072680A1/en not_active Abandoned
- 1992-07-02 ZA ZA924920A patent/ZA924920B/xx unknown
- 1992-07-09 ES ES92870101T patent/ES2109332T3/es not_active Expired - Lifetime
- 1992-07-09 EP EP92870101A patent/EP0527117B1/fr not_active Expired - Lifetime
- 1992-07-09 AT AT92870101T patent/ATE159719T1/de not_active IP Right Cessation
- 1992-07-09 DK DK92870101.0T patent/DK0527117T3/da active
- 1992-07-09 DE DE69222903T patent/DE69222903T2/de not_active Expired - Fee Related
- 1992-07-20 US US07/914,583 patent/US5258513A/en not_active Expired - Fee Related
- 1992-07-21 FI FI923314A patent/FI923314A/fi unknown
- 1992-07-23 NZ NZ243681A patent/NZ243681A/en unknown
- 1992-07-23 NO NO922922A patent/NO300683B1/no not_active IP Right Cessation
- 1992-07-23 AU AU20534/92A patent/AU648424B2/en not_active Ceased
- 1992-07-24 RU SU925052292A patent/RU2095353C1/ru active
- 1992-07-24 HU HU9202441A patent/HU218207B/hu not_active IP Right Cessation
- 1992-07-24 PL PL92295403A patent/PL169247B1/pl unknown
- 1992-07-24 PL PL92311241A patent/PL169646B1/pl unknown
- 1992-07-24 JP JP04198702A patent/JP3138540B2/ja not_active Expired - Fee Related
- 1992-07-24 KR KR1019920013231A patent/KR100221400B1/ko not_active IP Right Cessation
- 1992-07-24 IE IE242292A patent/IE922422A1/en not_active Application Discontinuation
-
1993
- 1993-06-18 UA UA93003144A patent/UA27749C2/uk unknown
- 1993-08-09 US US08/103,119 patent/US5348956A/en not_active Expired - Fee Related
-
1998
- 1998-01-28 GR GR980400187T patent/GR3026017T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO922922L (no) | 1993-01-26 |
| FI923314A (fi) | 1993-01-26 |
| DK0527117T3 (da) | 1998-05-18 |
| JPH06220026A (ja) | 1994-08-09 |
| DE69222903T2 (de) | 1998-03-26 |
| HUT66218A (en) | 1994-10-28 |
| UA27749C2 (uk) | 2000-10-16 |
| HU218207B (hu) | 2000-06-28 |
| FI923314A0 (fi) | 1992-07-21 |
| ATE159719T1 (de) | 1997-11-15 |
| JP3138540B2 (ja) | 2001-02-26 |
| AU648424B2 (en) | 1994-04-21 |
| CA2072680A1 (en) | 1993-01-26 |
| KR100221400B1 (ko) | 1999-09-15 |
| PL295403A1 (ko) | 1993-02-08 |
| KR930002327A (ko) | 1993-02-23 |
| GB9116039D0 (en) | 1991-09-11 |
| GR3026017T3 (en) | 1998-04-30 |
| RU2095353C1 (ru) | 1997-11-10 |
| EP0527117B1 (fr) | 1997-10-29 |
| ES2109332T3 (es) | 1998-01-16 |
| AU2053492A (en) | 1993-01-28 |
| NZ243681A (en) | 1997-06-24 |
| US5258513A (en) | 1993-11-02 |
| EP0527117A1 (fr) | 1993-02-10 |
| IE922422A1 (en) | 1993-01-27 |
| NO922922D0 (no) | 1992-07-23 |
| US5348956A (en) | 1994-09-20 |
| HU9202441D0 (en) | 1992-10-28 |
| DE69222903D1 (de) | 1997-12-04 |
| PL169247B1 (pl) | 1996-06-28 |
| ZA924920B (en) | 1993-04-28 |
| PL169646B1 (pl) | 1996-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300683B1 (no) | Substituerte cyklopropylamino-1,3,5-triaziner | |
| US5929089A (en) | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-Ht4 or H3 receptor ligands | |
| RU2129555C1 (ru) | Спиросоединения, содержащие пятичленные кольца, фармацевтический состав | |
| TWI543974B (zh) | 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途 | |
| KR101178658B1 (ko) | 오렉신 길항제로서의 설폰아마이드 | |
| PT98011B (pt) | Processo para a preparacao de pirazolopirimidinonas uteis como agentes antianginosos | |
| WO2007129111A1 (en) | Diazepine derivatives as 5-ht2a antagonists | |
| US5602125A (en) | Thienodiazepine derivatives as cholecystokinin and gastrin antagonists | |
| JPH0723364B2 (ja) | 新規な１−ピペラジンカルボキサミド誘導体 | |
| JPH01249767A (ja) | 興奮性アミノ酸レセプター拮抗物質として有用なテトラゾール誘導体 | |
| HU203233B (en) | Process for producing aryl piperazinyl alkoxy derivatives of cyclic imides and pharmaceutical compositions comprising such compounds | |
| CA2172162C (en) | Optically active imidazolidinone derivative and process for producing the same | |
| ES2219436T3 (es) | Nuevos derivados amino substituidos ramificados del 3-amino-1-fenil-1h (1,2,4)triazol, a los procedimientos para su preparacion, y a las composiciones farmaceuticas que los contienen. | |
| EP0497303B1 (en) | Carbamic acid derivatives and method for preparing the same | |
| US5371103A (en) | Thiochroman compounds | |
| EP0537993A1 (en) | Nicotinic activity of a series of arecolones and isoarecolones | |
| IE861826L (en) | N-diazinylpiperidine derivatives | |
| EP3027606B1 (en) | Compounds for enhancing the cognitive function | |
| LV10616B (en) | Substituted cyclopropylamino-1,3,5-triazines | |
| CA2143449A1 (en) | Optically active carboxamide derivative | |
| NO179206B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-amino-4-morfolino-6-propyl-1,3,5-triaziner | |
| JPH0558633B2 (ko) | ||
| NO177931B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive piperazinderivater | |
| EA004738B1 (ru) | Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции | |
| DE3542363A1 (de) | 1,4-dihydropyridin-derivate, ihre herstellung und sie enthaltende pharmazeutische zubereitungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN JANUARY 2002 |